OM
Opaleye Management Portfolio holdings
AUM
$494M
This Quarter Return
+75.06%
1 Year Return
+68.17%
3 Year Return
+608.37%
5 Year Return
+807.76%
10 Year Return
+24,567.29%
AUM
$495M
AUM Growth
+$495M
(+31%)
Cap. Flow
+$19.1M
Cap. Flow
% of AUM
3.86%
Top 10 Holdings %
Top 10 Hldgs %
52.26%
Holding
59
New
16
Increased
13
Reduced
8
Closed
11
Top Buys
| 1 |
Celldex Therapeutics
CLDX
|
$13.9M |
| 2 |
Fortress Biotech
FBIO
|
$10.3M |
| 3 |
Kiniksa Pharmaceuticals
KNSA
|
$8.78M |
| 4 |
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
$8.36M |
| 5 |
Ocular Therapeutix
OCUL
|
$7.18M |
Top Sells
| 1 |
FTSV
Forty Seven, Inc. Common Stock
FTSV
|
$36.8M |
| 2 |
APTO
Aptose Biosciences, Inc.
APTO
|
$5.63M |
| 3 |
KDMN
Kadmon Holdings, Inc.
KDMN
|
$4.83M |
| 4 |
Zymeworks
ZYME
|
$4.72M |
| 5 |
ODT
Odonate Therapeutics, Inc. Common Stock
ODT
|
$4.66M |
Sector Composition
| 1 | Healthcare | 91.31% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
MTEM
26
DELISTED
Molecular Templates, Inc.
MTEM
| $6.83M | 1.38% | 495,000 -38,400 | -7% | -$530K |
|
|
TCDA
27
DELISTED
Tricida, Inc. Common Stock
TCDA
| $6.55M | 1.32% | 238,300 +44,300 | +23% | +$1.22M |
|
|
CMRX
28
DELISTED
Chimerix, Inc.
CMRX
| $6.53M | 1.32% | +2,105,000 | New | +$6.53M |
|
29
MEI Pharma
MEIP
$160M
| $6.43M | 1.3% | +1,556,000 | New | +$6.43M |
|
30
FibroGen
FGEN
$47.8M
| $5.69M | 1.15% | 146,000 | – | – |
|
31
KalVista Pharmaceuticals
KALV
$678M
| $5.58M | 1.13% | 461,500 +236,500 | +105% | +$2.86M |
|
32
Catalyst Pharmaceutical
CPRX
$2.52B
| $5.34M | 1.08% | 1,155,000 +105,000 | +10% | +$485K |
|
33
BioXcel Therapeutics
BTAI
$59M
| $4.98M | 1.01% | +94,000 | New | +$4.98M |
|
|
EDAP
34
EDAP TMS
EDAP
$84.5M
| $4.65M | 0.94% | 1,878,500 -315,000 | -14% | -$779K |
|
35
KALA BIO
KALA
$78.8M
| $3.79M | 0.77% | 361,000 -421,000 | -54% | -$4.42M |
|
36
Cidara Therapeutics
CDTX
$1.66B
| $3.58M | 0.72% | 970,664 +64,608 | +7% | +$238K |
|
37
Liquidia Corp
LQDA
$2.38B
| $3.37M | 0.68% | +400,000 | New | +$3.37M |
|
38
Ardelyx
ARDX
$1.53B
| $3.26M | 0.66% | +471,600 | New | +$3.26M |
|
39
TELA Bio
TELA
$70.5M
| $3.24M | 0.65% | 250,000 +169,000 | +209% | +$2.19M |
|
|
AMRN
40
Amarin Corp
AMRN
$311M
| $3.15M | 0.64% | 455,000 | – | – |
|
41
Cardiff Oncology
CRDF
$140M
| $2.96M | 0.6% | +590,000 | New | +$2.96M |
|
|
ADMS
42
DELISTED
Adamas Pharmaceuticals, Inc.
ADMS
| $2.46M | 0.5% | +960,000 | New | +$2.46M |
|
43
Fennec Pharmaceuticals
FENC
$247M
| $1.43M | 0.29% | +171,000 | New | +$1.43M |
|
44
ESSA Pharma
EPIX
$11.4M
| $1.09M | 0.22% | +175,000 | New | +$1.09M |
|
|
AUTL
45
Autolus Therapeutics
AUTL
$399M
| $962K | 0.19% | +60,000 | New | +$962K |
|
46
Assertio
ASRT
$80.4M
| $754K | 0.15% | +880,000 | New | +$754K |
|
47
Dianthus Therapeutics
DNTH
$759M
| $385K | 0.08% | 51,225 -383,487 | -88% | -$2.88M |
|
|
BLRX
48
BioLineRX
BLRX
$16.2M
| $29K | 0.01% | 16,667 | – | – |
|
|
49
Zymeworks
ZYME
$1.12B
| – | – | -133,000 | Closed | -$4.72M |
|
|
PRVB
50
DELISTED
Provention Bio, Inc. Common Stock
PRVB
| – | – | -166,000 | Closed | -$1.53M |
|